Drugs / CHI-902
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04086342 Comparator | Jan 2020 → Jan 2021 | social phobia | Canopy Growth Corporation | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHI-902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04086342 ↗ |
| Known as | Cannabidiol | “No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in...” NCT04086342 ↗ |
| Known as | CBD | “No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in...” NCT04086342 ↗ |
| Route | Oral | “A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.” NCT04086342 ↗ |